LXRepair 2013-2023 has focused on providing decision aids to oncologists in the challenging landscape of cancer treatment. They emphasize the significance of profiling in predicting treatment toxicity and efficacy on tumors, leveraging over a decade of research by the French Atomic Energy Commission (CEA) on radiation impact on DNA. This has led to a thorough understanding of essential DNA repair mechanisms and the development of innovative biomarkers, paving the way for powerful personalized cancer treatment tools.
The startup, founded in 2013 in France, operates in the Biotechnology, Health Care, Health and Wellness, and Life Sciences industries. In their latest funding round on 10 October 2017, they secured a €14.98K Seed Round investment from Kreaxi, GENTIANE Participations, and CEA Investissement. To learn more, visit their website: www.lxrepair.com.